Steroid Induced Glaucoma Market
Report ID: SQMIG35I3722
Report ID: SQMIG35I3722
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35I3722 |
Region:
Global |
Published Date: September, 2026
Pages:
157
|Tables:
122
|Figures:
77
Global Steroid Induced Glaucoma Market size was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.27 Billion in 2025 to USD 2.05 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).
The global steroid‑induced glaucoma market tracks therapies and diagnostics aimed at preventing intra‑ocular pressure spikes caused by corticosteroid use. This niche emerged as ophthalmologists recognized that long‑term topical steroids, common after cataract surgery or in uveitis treatment, could trigger irreversible optic nerve damage. Early case series in the 1990s highlighted a rise in steroid‑responsive pressure elevations, prompting pharmaceutical firms to explore agents that counteract the molecular pathways of trabecular meshwork remodeling. Over the past decade, regulatory approvals of selective glucocorticoid receptor modulators and imaging tools have expanded the market size, turning a clinical warning into a commercial opportunity for patients worldwide and clinicians. Growth in the steroid‑induced glaucoma segment is driven primarily by rising prevalence of ocular inflammation and expanding use of intravitreal steroid implants for macular degeneration. As more physicians adopt dexamethasone or fluocinolone devices, the incidence of pressure‑related side effects escalates, creating demand for IOP‑lowering agents and monitoring platforms. Companies such as Alcon and Novartis have launched combination eye‑drops that target both inflammation and pressure, capitalizing on this need. Studies from Asian markets demonstrate that intervention reduces surgical referrals, thereby opening reimbursement pathways and incentivizing insurers to cover therapeutics. Consequently, investment in research and partnerships is expected to accelerate, widening market reach and fostering innovation.
How is AI-driven diagnostics reshaping the steroid‑induced glaucoma market?
AI-driven diagnostics are transforming the steroid‑induced glaucoma market by enabling earlier detection, personalized treatment pathways, and streamlined clinical workflows. Machine‑learning algorithms analyze optic nerve images and intra‑ocular pressure trends to flag subtle changes that traditional exams may miss. This capability reduces the risk of irreversible vision loss in patients using corticosteroids and supports ophthalmologists in making data‑rich decisions. Integration with electronic health records allows continuous monitoring and rapid referral to specialists. As clinicians adopt these tools, the market sees heightened demand for software platforms that can be paired with existing imaging devices, fostering a more proactive care model.April 2024, Eyenuk introduced an AI‑powered glaucoma screening platform that integrates with standard fundus cameras to identify steroid‑induced optic nerve changes. The tool accelerates diagnosis, reduces referral delays and expands access to early intervention, driving efficiency and growth in the market.
Market snapshot - (2026-2033)
Global Market Size
USD 1.2 Billion
Largest Segment
Intraocular Pressure Measurement
Fastest Growth
Optical Coherence Tomography
Growth Rate
6.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global steroid induced glaucoma market is segmented by diagnosis, treatment, patient group, end user and region. Based on diagnosis, the market is segmented into Intraocular Pressure Measurement, Optic Nerve Examination, Visual Field Testing, Optical Coherence Tomography and Others. Based on treatment, the market is segmented into Topical Antiglaucoma Medications, Steroid Discontinuation or Dose Reduction, Laser Therapy, Glaucoma Surgery and Others. Based on patient group, the market is segmented into Pediatric, Adult and Geriatric. Based on end user, the market is segmented into Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Intraocular Pressure Measurement segment dominates because it supplies the primary clinical metric for detecting steroid induced pressure elevation, enabling timely intervention. Clinicians rely on this simple, non invasive technique to differentiate steroid response from baseline, and its widespread availability across care settings supports routine monitoring. The method requires minimal equipment, can be performed by various eye care professionals, and integrates with electronic health records, reinforcing its central role in the market.
However, Optical Coherence Tomography segment is witnessing the strongest growth momentum because advances in imaging resolution and automated analysis are expanding its utility for early structural assessment of steroid damage. Clinicians are adopting OCT to capture subtle nerve fiber changes, creating new opportunities for precise monitoring and fostering market expansion.
Topical Antiglaucoma Medications segment leads because they provide immediate IOP reduction, essential for counteracting steroid induced spikes. Formulations such as prostaglandin analogs and beta blockers are readily prescribed, have well documented efficacy, and are accessible across outpatient settings, making them the preferred therapeutic choice. Their safety profile, ease of self administration, and ability to be combined with other agents enhance adherence and allow clinicians to tailor regimens to individual response. Continuous advancements in drug delivery technologies further reinforce their market position, ensuring sustained dominance.
Meanwhile, Laser Therapy segment is emerging as the key high growth area because minimally invasive procedures are gaining acceptance for steroid induced pressure control. Innovations in selective laser trabeculoplasty reduce treatment time and patient discomfort, encouraging clinicians to adopt laser as a viable alternative to chronic medication, thereby expanding market opportunities.
To get detailed segments analysis, Request a Free Sample Report
North America leads the global steroid induced glaucoma market due to a confluence of sophisticated healthcare ecosystems, extensive insurance coverage, and deep investment in ophthalmic research. The United States hosts a concentration of leading academic medical centers and pharmaceutical innovators that accelerate the development and adoption of advanced steroid‑based therapies and diagnostic technologies. Canada benefits from universal health care that ensures broad patient access and from collaborative public‑private initiatives that streamline clinical trials. Both countries maintain rigorous regulatory pathways that facilitate timely product approvals, while a well‑established network of eye‑care specialists drives early detection and management. These strengths, combined with heightened awareness among clinicians and patients, create a resilient demand environment that sustains market leadership. The region also attracts multinational manufacturers seeking to leverage its scale and expertise, further reinforcing its dominant position.
United States Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in the United States is propelled by a robust network of tertiary eye‑care centers and a culture of early adoption of innovative therapies. Pharmaceutical firms collaborate closely with leading academic institutions to conduct expansive clinical programs, while insurers provide comprehensive coverage that reduces out‑of‑pocket barriers. Regulatory pathways also streamline approvals for new steroid products, ensuring clinicians have timely access to effective treatment options.
Canada Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in Canada benefits from universal health coverage that guarantees equitable access to diagnostic and therapeutic services across provinces. National ophthalmology societies actively promote guideline adoption, while research collaborations between university hospitals and biotech firms foster innovation in steroid‑based treatments. Reimbursement policies reduce financial obstacles for patients, and a growing emphasis on early screening integrates glaucoma management into routine eye examinations, collectively enhancing market penetration and patient outcomes.
Europe experiences rapid expansion in the steroid induced glaucoma market driven by mature healthcare infrastructures, comprehensive reimbursement mechanisms, and a strong emphasis on clinical research. Harmonized regulatory frameworks across the European Union streamline product approvals, encouraging multinational investment. Germany leads with a dense concentration of specialized eye‑care centers and robust pharmaceutical R&D, while the United Kingdom benefits from agile policy reforms and a vibrant biotech ecosystem that accelerates adoption of novel steroid formulations. France shows emerging momentum as increasing awareness among clinicians and patients fuels demand for advanced diagnostic tools. The region’s commitment to patient‑centered care further amplifies adoption of early‑intervention strategies, reinforcing market momentum.
Germany Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in Germany is anchored by a high density of ophthalmology clinics and precision medicine. Government‑funded research programs collaborate with leading pharmaceutical firms to develop optimized steroid delivery systems, while insurance schemes provide broad coverage for diagnostics and treatment. The strong emphasis on evidence‑based guidelines ensures swift integration of new therapies into clinical practice, sustaining Germany’s position as the continent’s leading market for steroid induced glaucoma management.
United Kingdom Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in the United Kingdom is propelled by agile regulatory pathways and a thriving biotech sector that accelerates the introduction of cutting‑edge steroid formulations. National health services reimburse both diagnostic imaging and novel therapeutic agents, reducing financial barriers for patients. Collaborative networks between university ophthalmology departments and industry drive rapid clinical validation, while patient advocacy groups raise awareness of early detection, collectively fostering a fast‑growing market environment.
France Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in France is emerging as clinicians place greater emphasis on early diagnosis and personalized therapy. Health programs increasingly fund advanced imaging technologies, while reimbursement policies expand to cover newer steroid eye drops. Partnerships between French research institutes and multinational pharma companies stimulate development of innovative delivery mechanisms. Educational initiatives led by professional societies raise practitioner awareness, creating a supportive climate for market growth and patient access.
Asia Pacific is strengthening its position in the steroid induced glaucoma market through a combination of expanding eye‑care infrastructure, rising disease awareness, and strategic investment in pharmaceutical innovation. Japan’s advanced clinical research environment and strong regulatory pathways encourage rapid adoption of novel steroid delivery platforms, while South Korea’s focus on biotech development accelerates the introduction of next‑generation therapies. Growing middle‑class populations increase demand for high‑quality ophthalmic services, and regional collaborations among academic centers, manufacturers, and government agencies facilitate knowledge exchange. These dynamics collectively elevate the region’s capability to develop, approve, and disseminate cutting‑edge treatments, positioning Asia Pacific as an emerging hub for future market growth. In addition, local health ministries are implementing screening programs that prioritize early detection, thereby expanding the patient pool eligible for steroid‑based interventions.
Japan Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in Japan is characterized by a strong emphasis on clinical excellence and innovation. The nation’s health‑care reimbursement system ensures access to sophisticated diagnostic imaging and advanced steroid eye drops. Collaborative research between university hospitals and leading pharmaceutical companies drives the development of targeted delivery systems, while regulatory agencies maintain pathways for product approval. These factors sustain Japan’s leadership in adopting cutting‑edge therapies for steroid induced glaucoma.
South Korea Steroid Induced Glaucoma Market
Steroid Induced Glaucoma Market in South Korea is driven by an evolving biotech sector and strong government support for ocular research. Reimbursement policies cover both conventional steroid eye drops and newer sustained‑release formulations, facilitating broad patient uptake. Partnerships between Korean academic institutions and multinational pharmaceutical firms accelerate clinical trials for innovative delivery technologies. Additionally, health campaigns emphasize early detection, expanding the diagnosed patient base and reinforcing the market’s growth trajectory.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Improved Diagnostic Techniques
Expanded Therapeutic Options
High Treatment Costs
Limited Healthcare Infrastructure
Request Free Customization of this report to help us to meet your business objectives.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the global steroid induced glaucoma market is projected to reach $2.05 billion by 2033 driven first by improved diagnostic techniques that enable earlier detection and boost demand for monitoring tools, while a second driver is the expanding therapeutic options including new ocular hypotensive agents and micro‑invasive procedures that broaden treatment choices. The intraocular pressure measurement segment remains dominant because it provides the primary metric for spotting steroid‑related pressure spikes. North America leads the market thanks to its sophisticated healthcare system, strong insurance coverage and active research environment. However high treatment costs pose a restraint, limiting uptake in price‑sensitive regions.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 1.2 Billion |
| Market size value in 2033 | USD 2.05 Billion |
| Growth Rate | 6.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Steroid Induced Glaucoma Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Steroid Induced Glaucoma Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Steroid Induced Glaucoma Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Steroid Induced Glaucoma Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
